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Резюме. Изучали влияние интервальных гипоксически-гипероксических тренировок (ИГГТ) на активность, 
экспрессию белка и мРНК Mn-супероксиддисмутазы в митохондриях миокарда крыс после влияния острой гипок-
сии. Показано, что использование ИГГТ приводит к снижению гиперактивации Mn-СОД и индуцирует экспрессию 
белка данного антиоксидантного фермента в митохондриях миокарда после действия острой гипоксии. 
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Abstract. The influence of intermittent hypoxic-hyperoxic trainings (IHHTS) on the  activity, expression of protein 
and mRNA of Mn-superoxide dismutase in myocardial mitochondrias of rats has been studied after the influence of acute 
hypoxia. It has been shown that the use of  IHHTS results in a lowered hyperactivation of Mn-SOD and an enhancement of 
the protein expression of this particular enzyme in myocardial mitochondrias after the action of acute hypoxia. 
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Introduction. The tuberculosis (TB) epidemic 
is on the rise in many countries, including Ukraine. 
If left untreated the active form of TB will kill two of 
every three people.  
An important factor of the incidence rate of tu-
berculosis is a rapid spread of the strains of the myco-
bacteria of tuberculosis (MBT) resistant to antituber-
culous agents (ATA). This problem is further compo-
unded by HIV coinfection, since one-third of AIDS-
related deaths results from TB. Ukraine has the highe-
st prevalence of TB/HIV co-infection in Eastern Euro-
pe (van der Werf et al. 2006). Multidrug-resistant 
tuberculosis has emerged as a global epidemic, with 
425,000 new cases estimated to occur annually. The 
global human immunodeficiency virus (HIV) infec-
tion epidemic has caused explosive increases in TB 
incidence and may be contributing to increases in 
multidrug-resistant tuberculosis prevalence. 
Institutional outbreaks of MDR-TB have prima-
rily affected HIV-infected persons. A delayed diagn-
osis, inadequate initial treatment and prolonged infe-
ctiousness led to extraordinary attack rates and case-
fatality rates among HIV-infected persons. Whether 
this sequence occurs in communities is less clear. 
Multidrug-resistant tuberculosis appears not to cause 
infection or disease more readily than drug-
susceptible TB in HIV-infected persons. HIV infec-
tion may lead to a malabsorption of anti-TB drugs 
and acquired resistance. HIV-infected patients with 
multidrug-resistant tuberculosis have unacceptably 
high mortality; both antiretroviral and antim-
ycobacterial treatments are necessary [9]. 
The treatment of the multidrug-resistant forms 
of pulmonary tuberculosis characterized by a rapid 
MBT propagation, massive infiltrative-caseous 
changes in the lungs, numerous destructions of the 
pulmonary tissue, pronounced intoxication syn-
drome, encounters considerable difficulties. Inten-
sive chemotherapy with the use of ATA of the 1st and 
2nd lines is not always effective, disease progression 
often against a background of therapy, resulting in 
fatal outcomes. The treatment of such forms is con-
siderably complicated due to an insufficient amount 
of second-line antituberculous agents in case of ex-
tensive MBT resistance, their poor tolerance and a 
high cost of therapeutic regiments [4]. The principal 
cause of a low efficacy of treatment of patients af-
flicted with MBT is the insufficient efficacy of the 
medications of the 2nd line as compared with isoni-
azid and rifampicin, acting bactericidally on MBT. 
All the second-line antituberculous agents (except 
fluoroqiuonolones) act on the MBT bacteriostati-
cally, their minimal inhibiting concentration in rela-
tion to mycobacteria is essentially lower (10-20 
times) than that of isoniazid and rifampicin [5]. 
The outcome of such therapy depends on many 
factors – the nature and duration of the tuberculous 
process, the number of medications to which MBT is 
resistant, chemotherapeutic regimens – their inten-
sity, optimality, tolerance and duration, the availabil-
ity of necessary drugs, control and treatment and 
other factors.  
According to international and domestic recom-
mendations [3] pertaining to the treatment of patients 
with MRT of the lungs or a suspicion of it there exist 
several treatment regimens and a few approaches to a 
patient’s treatment, requiring the administration of a 
repeated course of chemotherapy [4, 6, 8]. But nei-
ther of the approaches is universal, so long as it has 
both advantages and disadvantages [7]. To date the 
best policy as to the management of patients with a 
repeated treatment and a high risk of multidrug-
resistance has not been determined [5]. 
The objective of research. To study risk 
groups, concerning the formation of multidrug-
resistant pulmonary tuberculosis and raise the effi-
cacy of its treatment in patients in whom susceptibil-
ity of the causative agent to antituberculous agents is 
unknown. 
Material and methods of the research. 227 
previously treated patients afflicted with new-onset 
tuberculosis and disease relapses have been exam-
ined, using a clinical, roentgenological, clinico-
laboratory, microbiological, statistical methods. 
Results of the investigation and the subject 
under discussion. Among the persons under study 
(227 patients) there were 33 patients in whom a fail-
ure of the first course of chemotherapy (CT) was 
registered, 90 persons were with a suspended course 
of treatment for more than 2 months, 18 persons with 
a failed repeated course (there were both patients 
with NOTL and with recurrences) who were treated 
up to 10 months according to the second clinical 
category. 86 patients suffered from a TB relapse and 
who were not treated according to the second clinical 
category (Table 1). 
It has been established that among 227 exami-
nees the level of MBT multiresistance fluctuated 
from 43,3% in patients with suspended treatment to 
88,8% in patients with a failure of a repeated course 
of chemotherapy. 
However, in order to define the degree of prob-
ability in each group of these patients we made use 
of the definition of the odds ratio concerning the 
presence of multidrug resistance in them. These find-
ings are presented in Table 2. 
A correlation between a patient’s medical his-
tory relative to the previous treatment and the pres-
ence of multidrug resistance was evaluated by means 
of the odds ratio (OR) according to a 4-column table 
complied on the principle of comparing two groups 
with the presence and absence of a sign that is under 
study. If the value of the ratio of chances for un-
wanted sequelae is less than 1 this is an indication of 
a positive effect of the factor in question directed at 
reducing a risk of this sequela. 
Thus, with the rate of multidrug resistance in 
the group of 22 % previously treated patients that 
constituted 56,8 %, we found out that reliably vul-
nerable groups concerning multidrug resistance are 
patients with a failure of the 1st and repeated course 
of chemotherapy with equally high values of the 
odds ratio 5,5 and 6,08 (p>0,05) respectively. In pa-
tients with a suspended course of treatment and dis-
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Table 1 
The structure of the cohort of patients with pulmonary tuberculosis who require retreatment  
based on the type of a case of the tuberculosis disease 
Table 2 
The ratio of chances as to the presence of multidrug resistance in patients with NOTL  
and disease recurrences, requiring the administration of retreatment 
Fig. 1. Efficiency of chemotherapy regimens 
The number of patients 
Total 
The type of a case of the tuberculosis disease 
Suspended treatment Failure of the 1
st course 
of treatment 
Failure of the 2nd 
course of treatment Tuberculosis relapse 
Abs. % Abs. % Abs. % Abs. % 
227 90 39,6 33 14,5 18 7,9 86 37,9 
Groups of patients treated earlier 
Multidrug resistance of MBT 
OR (95 % CI) There is There isn’t 
abs. % abs. % 
Failure of the 1st course of CT 29 87,9 4 12,1 5,5 (1,87-16,18) 
Suspended treatment 39 43,3 51 56,7 0,58 (0,35-0,95) 
Failure of the 2nd course of CT 16 88,8 2 11,2 6,08 (1,36-27,05) 
Recurrence 45 52,3 41 47,7 0,83 (0,5-1,37) 




























ease relapses there exist a relative risk of the pres-
ence of multidrug-resistance with the odds ratio – 
0,58 and 0,83 respectively that does not differ con-
siderably between themselves (p>0,05), however, it 
is reliably lower than in patients of the previous 
groups (p<0,05). 
We have carried out a comparative analysis of 
the efficiency of various regimens of chemotherapy 
in patients with pulmonary tuberculosis with un-
known susceptibility of tuberculosis mycobacteria to 
antimycobacterial drugs among groups of risk of the 
development of multidrug resistant tuberculosis. The 
efficiency of the standard and individual regimens of 
chemiotherapy was evaluated in 6 months since the 
initiation of treatment. 
Іn spite of an individual selection of chemother-
apy, preference was given to the standard regimen of 
chemotherapy (p>0,05). 
The next evaluation of regimens was carried out 
on discharging the patients from the in-patient de-
partment, in 16,8±7,2 months on the average. 
The most effective regimen of chemotherapy in 
patients with multi-drug resistant tuberculosis was 
the standard one.  
The findings obtained as a result of the research 
carried out by the authors agree with those of other 
studies that point out the efficiency of the empiric 
regimen of chemotherapy towards the resistance of 
tuberculous mycobacteria at the expense of prescrib-
ing 5-7 drugs for the purpose of preserving rather a 
high likelihood of the fact that tuberculosis myco-
bacteria will retain susceptibility at least to 4 of 
them. Evaluating the regimens of chemotherapy on 
discharging from hospital, regardless of an individ-
ual selection of chemopreparations, the standard 
regimen turned out to be more effective (EK (Am) 
Cessati   
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Fig. 2. Efficiency of the chemotherapeutic regimen upon discharging from hospital 
ZEt ( Pass) Q or EZEtPASSQ) on the basis of using 
2nd line medications and fluoroquinolones.  
Conclusions 
1. A very high risk of multidrug-resistant tuber-
culosis of the lungs is characteristic of patients with 
a failure of the first course of chemotherapy (87,9 %) 
and a failure of the repeated course (88,8 %); a high 
risk of multidrug-resistant tuberculosis is inherent to 
patients with tuberculosis recurrence and suspended 
treatment in compliance with the 1st category (with 
the rate of 52,3 % and 43,3 % respectively). 
2. It is advisable to prescribe standard regimens 
of chemotherapy based on the 4th category to patients 
with a failure of the first and repeated course of che-
motherapy in case of the absence of the test of medi-
cal susceptibility of mycobacteria to antituberculous 
drugs of the first line.  
3. While comparing the efficacy of  different 
regimens of chemotherapy in patients afflicted with 
pulmonary tuberculosis, it has been established that 
the most effective regimen is the empiric regimen of 
chemotherapy (EZS(К)PASQ or EZK(Pt/Сap)CsQ) 
prior to evaluating tuberculous mycobacteria resis-
tance (the basic course), at the expense of prescrib-
ing a combination of 5-7 drugs. During a stage of 
continuing treatment, evaluating the regimens of 
chemotherapy upon discharging from hospital, the 
standard regimen turned out to be more effective 
(EK(Am)ZEt(PASS)Q or EZEtPASSQ at the ex-
pense of using second-line drugs and fluoroqui-
nolones. 
4. The analysis of the efficacy of the most ra-
tional regiments of chemotherapy of patients with 
pulmonary tuberculosis with due regard for an 
evaluation of antimycobacterial susceptibility of the 
causative agent, enabling to improve the results of 
chemotherapy and forestalling the development of 
multiresistant forms at HIV-infected persons. 
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АНАЛИЗ ЭФФЕКТИВНОСТИ ХИМИОТЕРАПИИ МУЛЬТИРЕЗИСТЕНТНОГО  
ТУБЕРКУЛЕЗА В УСЛОВИЯХ РАСПРОСТРАНЕНИЯ ЭПИДЕМИИ ВИЧ/СПИДА 
Л.Д.Тодорико, А.В.Бойко, И.В.Еременчук, Ю.М.Лесюк 
Резюме. Проведен анализ еффективности наиболее рациональных режимов химиотерапии больных туберку-
лезом легких с учетом оценки антимикобактериальной чувствительности возбудителя, что дает возможность улуч-
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шить результаты химиотерапии и предупредить развитие мультирезистентных форм, в том числе у ВИЧ-
инфицированных пациентов. 
Ключевые слова: частота мультирезистентности микобактерий туберкулеза, ВИЧ/СПИД, впервые 
диагностированный туберкулез легких, рецидивы туберкулеза, химиорезистентность. 
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Резюме. Проведено аналіз ефективності найбільш раціональних режимів хіміотерапії хворих на 
туберкульоз легень з урахуванням оцінки антимікобактеріальної чутливості збудника, що дає можли-
вість покращaти результати хіміотерапії та запобігти розвитку мультирезистентних форм, у тому числі, 
у ВІЛ-інфікованих пацієнтів. 
Ключові слова: частота мультирезистентності мікобактерій туберкульозу, ВІЛ/СНІД, вперше діаг-
ностований туберкульоз легень, рецидиви туберкульозу, хіміорезистентність. 
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Резюме. Патогенетична терапія, спрямована на 
підвищення імунітету, опірності імунітету до туберку-
льозної інфекції, є обов’язковим компонентом лікуван-
ня хворих на хіміорезистентний туберкульоз легень. 
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лікування, патогенетичні засоби. 
Проблема фармакотерапії туберкульозу стала 
на сьогодні пріоритетним питанням у зв’язку з 
недостатньою ефективністю методів традиційної 
терапії, спрямованої на пригнічення бактеріальної 
популяції. Це пов’язано, перш за все, із збільшен-
ням відсотка пацієнтів із множинною медикамен-
тозною стійкістю до антимікобактеріальних пре-
паратів (АМБП) та поєднанням із ВІЛ-інфекцією – 
захворюванням, що розвивається в результаті три-
валого персистування вірусу імунодефіциту люди-
ни (ВІЛ) у лімфоцитах, макрофагах та клітинах 
нервової системи і характеризується прогресую-
чою деструкцією імунної системи [8].  
Патогенетична терапія, спрямована на підви-
щення імунітету, опірності організму до туберку-
льозної інфекції, є обов’язковим компонентом 
комплексного лікування хворих на туберкульоз.  
Формуванню мікобактерій туберкульозу 
(МБТ), резистентних до хіміопрепаратів, сприяє, 
насамперед, пригніченню клітинного імунітету, 
яке вперше виникає під впливом факторів ризику 
і в подальшому спричиняє розвиток туберкульозу 
в інфікованої людини.   
Клінічні прояви туберкульозу легень, його 
перебіг та результати лікування тісно пов’язані з 
неспецифічною реактивністю хворого, його ком-
пенсаторними можливостями, станом імунної 
системи, особливо за наявності множинної резис-
тентності МБТ до АМБП [8]. 
Відомо, що у хворих на вперше діагностова-
ний туберкульоз, спричинений поліхіміорезисте-
нтними МБТ, відмічається порушення балансу 
між оксидантними та прооксидантними власти-
востями крові, що проявляється підвищенням у 
сироватці крові вмісту продуктів ліпопероксида-
ції на тлі зниження активності ферментів системи 
антиоксидантного захисту [2].  
У хворих на туберкульоз легень із порушен-
нями метаболічного гомеостазу успішно застосо-
вується Флуімуцил – антибіотик ІТ та Тимоген. 
Флуімуцил – антибіотик ІТ – це лікарський засіб, 
до складу якого входять N–ацетилцистеїн та тіам-
